Establishing the ecotoxicological profile of a chemical can be challenging due to the complex nature of the ecosystem.

The transformative Labcorp approach is based on an operating model enabled by continuous innovation across our infrastructure. The result is real-time access to clinical trial data, allowing proactive mitigations and confident decisions, faster.

Literature reviews offer a cost-efficient approach to appraise the currently published literature to gather evidence, address potential data gaps and support downstream market access activities.

Immunogenicity assays that are developed and validated to support preclinical studies are often validated in the same way as clinical assays, even though the purpose of the data is very different.

We were approached by a client about an older substance originally registered under Notification of New Substances (NONS), but assessed under Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH) regulation.

Health economic analyses complement the existing clinical evidence base to support a product's value proposition. This additional evidence helps to support the case for unmet need (cost of illness), affordability and value for money.

We were was approached by a client to carry out bumblebee acute contact and oral toxicity studies (OECD 246 and 247) for a plant protection product.

We were approached by a European company producing a standard herbicide for maize who had been asked by the regulator to conduct a study to provide data to refine the small mammal risk assessment.

More than 350 million people live with over 7,000 identified rare diseases worldwide. Being patient-centric calls for innovation in service (not just technology), particularly for specialized needs associated with rare diseases. Today, along with an increased ability to treat these diseases, we see extra pain points in the patient journey.